As the field of ketamine therapy evolves, practitioners are exploring ways to make it an even more effective tool for addressing depression and other psychiatric conditions by combining it with a growing range of adjunctive therapies, such as transcranial magnetic stimulation (TMS) and esketamine (Spravato).
This month’s webinar will provide an overview of the mechanisms of action, efficacy data, and clinical applications of these therapies and others, with a focus on best practices for adjunctive use. Our panelists will address patient selection criteria, safety considerations, and strategies for sequencing or combining treatments. Real-world case examples will illustrate practical approaches to integration across diverse clinical settings.
In this webinar, experts will break down:
- Appropriate patient populations and selection criteria for adjunctive therapy
- Current evidence regarding the efficacy and safety of combining or sequencing these treatments
- Mechanisms of action and clinical indications for ketamine, TMS, and esketamine (Spravato)
- Best practices for integrating these modalities into individualized treatment plans for patients with mood disorders
As always, there will be ample time for audience Q & A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Tuesday, September 30th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.

